Applications of genomics in NSCLC

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

“…On the other hand, BRCA1-defective cells have lower levels of the ERCC1, whose expression has been correlated with significantly impaired response to CDDP. 19,20 In the same cells we also found low RRM1, whose expression predict longer survival in lung cancer patients treated with gemcitabine/CDDP. 21 Several studies have been performed to define the molecular basis of different chemosensitivity profile in "triple negative" breast tumors and, in particular, BRCA1-defective cancers.…”

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

“…In the present study, analysis of BRCA1 protein expression in 101 NSCLC patients showed that 52 patients positively expressed BRCA1, and 49 patients presented negative BRCA1 expression, amounting to a BRCA1 positive expression rate of 51.5 % (52/101). No significant correlation between BRCA1 protein expression and age, gender, smoking status, histopathological morphologies, and clinical tumor stages was observed, which is consistent with the findings of most other studies [15,16].…”

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

“…Impaired DNA repair ability can increase genomic instability and tumorigenesis [3]. Single nucleotide polymorphism in DNA repair genes can impair DNA repair mechanisms [4].…”